Editorial Comment
The Transplanted Heart in the Pediatric Patient Growth or Adaptation Linda J. Addonizio, MD, and Welton M. Gersony, MD uring the past decade, cardiac transplantation D has become the treatment of choice for many children with intractable myocardial disease, and the prognosis for pediatric recipients has steadily improved.'-4 The investigative issues that have been most emphasized in recent years pertain to mortality risk factors, morbidity, and quality of life. [5] [6] [7] Although linear body growth has been demonstrated in pediatric patients, questions related to cardiac growth have remained largely uninvestigated and therefore unanswered.8 '9 The initial query is one of definition. Should growth be considered an enlargement of dimensions, an increase in mass, or both? If mass increases, which cellular elements increase in size and/or number?
In a monograph by Zak, cardiac growth is considered to be controlled by two sets of factors. 10 Intrinsic, or time-dependent, factors include cardiac morphogenesis, as well as the ability of myocytes to undergo hyperplasia and be affected by humoral growth substances. These changes are not associated with the functional demands placed on the heart. Extrinsic factors are those that are related to contractile function: the cardiac response to altered hemodynamics. In normal children, extrinsic factors are thought to be responsible for most of cardiac growth after the neonatal period. Pertaining to rate of growth, Rakusanll cites the early work of Falk, who in See p 1433 1901 described the growth of a child's heart related to age. This observation and subsequent studies have found that the human heart has the greatest increase in weight during the first postnatal year. The weight of the heart doubles by 6 months and triples by 1 year of age. Afterwards, growth of the heart becomes more gradual and is proportional to increases in body weight of the individual, not to age. Furthermore, studies in animals as well as humans have shown that with decreased body weight from fasting or starvation, the heart weight is the same as that of normal younger animals of similar body weight.1' Body weight as the probable determinant of the functional load placed on the heart appears to be the most important influence on normal cardiac weight and growth throughout early life. Disproportionate hypertrophy may be caused by extreme changes in functional demands on the heart secondary to normal adaptation to training, outflow obstruction, systemic hypertension, myocardial ischemia, or myocardiopathy. Will a transplanted heart in a newborn infant grow to adult size along with the child, and will the dimensional growth of the organ allow adequate function over time? It has been demonstrated that the cardiac silhouette on radiography of infants transplanted in the first month of life enlarges concomitantly with the thorax at age 4-5 years. Furthermore, echocardiographic data have shown increased cardiac dimensions with body growth.'2"3 A number of centers have reported prepubescent transplant recipients who have maintained normal cardiac outputs and hemodynamics through adolescence, with follow-up periods of more than 5 years.27"14 Transplant patients have a normal active lifestyle without symptomatology, indicating that the cardiac allografts have adapted to changes in demand as body mass increased. Does this represent cardiac growth or physiological adaptation of a small heart to increased cardiac output requirements? Hosenpud et al'5 reported hemodynamic data on a series of adult patients 3 months after transplantation, who received significantly undersized hearts for their body size. They found that although cardiac output was maintained at normal levels for the recipient's size, the patients who received undersized hearts still had to rely on increased heart rates and elevated filling pressures to achieve this normality. The question as to whether pediatric donor hearts have an increased ability to grow or adapt, as compared to adult hearts, has not been answered.
The hemodynamic, macrodimensional, and cellular aspects of cardiac growth in pediatric cardiac transplant patients are addressed by Bernstein et al'6 in this issue of Circulation. These authors studied the changes in cardiac dimensions as measured by echocardiograms in 13 pediatric cardiac transplant recipients. The study population included infants and older children; the mean age was 5 years with a range from 0.4 to 12.8 years. The mean follow-up period was 3 years (range, 1.3-5.8 years). Data were collected at one early and one late time point after transplantation, and the results were compared to normal pediatric echocardiographic data stratified into percentile classes according to body surface area. The early measurements were taken at a mean of 5.7 months after transplant, and the late data were obtained at 37.9 months. The mean change in body surface area over the time period of the study was 0.24 m2 (range, 0.12-0.5 m2i). Donor hearts came from patients who were significantly larger than the recipientsa mean of 32% larger by weight and 24% taller. The author's definition of normal growth was a lack of percentile class change in echo dimensions between early and late follow-up. Similarly, failure of growth was defined as a decline in class over time. The authors searched for extrinsic conditions that could affect the validity of the growth data and/or account for pathological hypertrophy (e.g., obstruction at anastomotic sites, systemic hypertension) and found none in this series of patients. In addition, the relation between the number of rejection episodes and ventricular wall thickness was explored. The authors also presented histological morphometric analyses of endomyocardial biopsies of five of the 13 patients. Myocyte fiber width was measured as an index of hypertrophy, and myofibril and mitochondrial volume fractions were calculated from electron micrographs and compared with those of normal adult controls. The issue of myocyte hyperplasia was not addressed.
On the basis of the stratification data, the authors concluded that normal chamber growth occurs. However, the impact of the oversized donor hearts on the interpretation of the growth data requires more emphasis. In three of the 13 patients in this study who were in the smaller body surface area range, left ventricular end-diastolic dimension (LVEDD) diminished by a percentile class, and these individuals thus did not demonstrate normal chamber growth. These children may have received large donor hearts and therefore had little demand for increased LVEDD with body growth. Even patients who received a large donor heart and remained in the same stratification class may have done so not because of cardiac growth but as a result of "growing into" the donor heart size. Three children experienced a decreased right ventricular end-diastolic dimension (RVEDD) percentile class. This observation may also be explained by donor heart size but in addition could be a reflection of right ventricular failure perioperatively in some patients. Therefore, it might be expected that when donor hearts are "large" for the recipient's body, dimensions that began in the higher stratifications might be expected to diminish for both LVEDD and RVEDD. The requirements for increased cardiac output with body growth may not be a stimulus for uniform growth in a heart that is already large. Dimensions in class 1 or 2 might be expected to increase more rapidly because of growth whereas class 5or 6-sized hearts may regress in relative size although still "growing" somewhat. The method of stratifying echo dimensions by body surface area appears to be a useful one but may require modification to more precisely assess whether the change in chamber size of these patients is appropriate for body growth. 17 The authors reported significant left ventricular, septal, and right ventricular hypertrophy both by echo measurement of wall thickness and by direct measurement of the myocyte fiber width. There was no correlation between rejection frequency and wall thickness. The first echo evaluation in this study was a mean of 5.7 months after transplantation. It has been established that hypertrophy in transplanted hearts, especially in infants and small children, occurs much earlier postoperatively, often within the first few weeks.18 Because the early data points were obtained so many months after the operation, valuable information may have been lost regarding growth versus inappropriate hypertrophy
The histological analyses produced some interesting and provocative results. The myocyte width in the transplanted hearts were substantially higher than controls, and this would be indicative of myocardial hypertrophy in these allografts. The patients, who ranged in age from 1 to 8 years, had a measured myocyte width of 10-15 ,um. The authors' measured as well as literature quoted control values were 6-9 gim. However, these data may be controversial because other reports"" l9 have indicated normal human myocyte width to be in the range of 10-18 gm for older children and adults.
Using these values as controls, the transplant patients might have fallen in the normal instead of the hypertrophied range. Vliegen et al'9 discusses the importance of the preparation of the tissue sections to prevent swelling or shrinkage of the myocytes, and for consistency he and his coworkers suggest that only cells with intercalated discs visible at each end should be measured. The study by Bernstein et al does not give the details of preparation of tissue sections. If the myocytes are more normalsized than thought in the present study, it could be speculated that the "hypertrophy" seen by echocardiography could be secondary to fibrosis or an increase in interstitial matrix. The matrix surrounding the myocardial cells (i.e., collagen, fibroblasts, vascular smooth muscle, and endothelial cells), which comprise the remaining two thirds of the cells in the heart, is also capable of proliferation.20 Even if the myocytes are indeed wider than normal for the age of the donor organ, questions of definition remain. The authors make the point that their observed normal myocyte volume fraction in the presence of wider myocytes would be indicative of either normal growth or physiological hypertrophy. However, the larger-than-normal myocytes could suggest that although the hearts may appear to be "growing," the organs are actually adapting to an abnormal physiological challenge by becoming more hypertrophied than normal. Perhaps the myocytes are thicker because of the effects of chronic denervation, high levels of catecholamines, and from a constant immunological barrage.
Growth of the heart occurs by hyperplasia of the myocardial cells or physiological hypertrophy of the existing cells. Some reports indicate that hyperplasia no longer occurs after early postnatal life, and that myocardial cells are thereafter only able to increase in size.1"2' However, the apparent lack of hyperplastic growth potential in the nonneonatal heart does not mean that the ability to synthesize DNA is totally lost in these cells; it may only be quiescent. According to Zak, the number of cardiac nuclei containing more than one set of chromosomes is increased when adult hearts are undergoing hypertrophy.102' Furthermore, replication of DNA has been induced in mitotically inactive nuclei by infection with polyoma and SV40 viruses and thereby enabled sustained cardiac myocyte proliferation to occur.21 This may add support to the idea that under certain clinical stresses or with certain stimuli, myofibers from immature hearts beyond the neonatal period could again undergo a hyperplastic response. Schneider and Parker,22 in a review on the actions of peptide growth factors on cardiac myocytes, discuss the evidence that these substances may be released in response to myocardial injury and then are able to turn on fetal gene and/or dilatation. 1625 expression in the differentiated myocyte. It is conceiv-able that immunological damage from rejection in the cardiac allograft, perhaps concomitantly with other stresses such as infection, may cause release of some potential growth factors that could induce hyperplasia in pediatric cardiac allografts. 18 The eventual elucidation of the effects of these growth factors on cardiac myocytes alone or in concert with other hormonal agonists may further increase our understanding of both normal and pathological growth of the heart. This seminal study by Bernstein et al provides an excellent beginning to answering important questions regarding cardiac growth and adaptation. Continued follow-up of these and other children over the years undoubtedly will lead to an ever-increasing data base on which to proceed. It is known that the heart definitely increases in size, apparently almost always appropriate to the hemodynamic demands of the growing body. More precise histological methods to quantify all the cellular elements and matrix combined with perhaps serial measurements of mass by magnetic resonance imaging might further help clarify the issues related to growth, adaptation, and normal versus abnormal hypertrophy. Future studies will be necessary to determine the nature of donor cardiac growth and whether it is a phenomenon that occurs only in the immature heart.
